Our Services

Blood and Marrow Transplantation (BMT) and Cellular Therapies

Description of Services


Our Mission

The clinical mission of the Division of Blood and Marrow Transplantation and Cellular Therapies is to design and test disease-specific and biologically rational novel reduced-toxicity transplantation regimens for patients with high-risk leukemia or lymphoma, and for those afflicted with life-threatening inherited conditions that can lead to bone marrow failure, immune deficiency, autoimmune diseases, and neurodegenerative conditions including but not limited to leukodystrophies and mucopolysaccharidosis syndromes.
Our translational research mission focuses on developing new cellular immune therapy programs for cancer and viral infections and testing the use of bone marrow transplantation following solid organ transplant to establish immunity, tolerance, and extend organ survival.

Blood and marrow transplantation (BMT) is used successfully to treat a number of cancers, blood diseases, and immune disorders that were once considered incurable. Our proactive patient care with close monitoring of the immune system has resulted in unsurpassed outcomes since 2010. Our one-year transplant-related mortality is below 10 percent for all allogeneic marrow, PBSC, and cord blood transplants and ~5 percent for our institutional reduced-intensity allogeneic transplant trial.

The division has a strong programmatic focus on reduced-intensity/toxicity cord blood, bone marrow, and stem cell transplantation for inherited disorders. In 2008, Dr. Szabolcs designed the first ever reduced intensity cord blood transplantation trial for inborn errors of metabolism with similar engraftment rates as ablative therapies, Biol Blood Marrow Transplant. 2014 Mar;20(3):326.

Our current, further refined Pitt trial  is leading in safety and efficacy saving children/young adults from not only toxic deaths but also from brain, lung, liver, heart, GU, and other organ toxicities. The absence of severe, or extensive GVHD and improved quality of life permits early return to their local communities while our integrated Ronald McDonald House offers comfortable housing during the weeks away from home. 

The division has a clinical research focus on Crohn’s disease  and other autoimmune disorders. Novel, reduced toxicity/intensity protocols are opening for advanced leukemia, sickle cell disease, and thalassemia.

In collaboration with other University of Pittsburgh investigators, we are the only center in the world to offer tandem lung and bone marrow transplantation for pediatric and adult patients with immunodeficiencies who have progressed to pulmonary failure. Ongoing collaborations at Pitt will pioneer further applications.

Comprehensive Care Expertise Environment
Comprehensive care Highly trained, highly respected Caring for the whole child and family
A Range of Services

We use blood and marrow transplant to treat cancers, blood diseases, and immune disorders once considered incurable.

Highly Trained, Highly Respected

Our doctors are pioneers in their respective fields, and are striving to improve cellular therapies for childhood cancers and blood diseases.

Caring for the Whole Child and Family 

We're dedicated to helping the child — and the entire family — through the BMT process.

  • Increase/Decrease Text Size
  • Print This Page
Last Update
May 20, 2015